ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1483

Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1627

Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1495

Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1456

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1037

Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 0910

Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1157

Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1196

Relation of Different Types of Antidepressants Use to Pain Severity and Measures of Pain Sensitization in Kneeosteoarthritis

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1180

Relationship Between Changes in Physical Activity and Early Onset Knee Osteoarthritis in Individuals After ACL Reconstruction

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1442

Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1393

Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1192

Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1133

Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1350

Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0885

Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions

Genetics, Genomics & Proteomics Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].